Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 74, No 5 (2023)
Original paper
Submitted: 2023-07-01
Accepted: 2023-08-16
Published online: 2023-10-23
View PDF Download PDF file View HTML
Get Citation

Association of plasma galectin-3 and fetuin-A levels with diabetic retinopathy in type 2 diabetes mellitus patients

Min Li1, Meimei Tian1, Yuling Wang2, Huijie Ma34, Yaru Zhou1, Xinli Jiang5, Yan Liu1
DOI: 10.5603/ep.96300
·
Endokrynol Pol 2023;74(5):536-543.
Affiliations
  1. Department of Endocrinology, The Third Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China
  2. Department of Internal Neurology, The Third Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China
  3. Department of Physiology, Hebei Medical University, Shijiazhuang City, Hebei Province, China
  4. Hebei Collaborative Innovation Centre for Cardio-Cerebrovascular Disease, Shijiazhuang, China
  5. Department of Ophthalmology, The Third Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China

open access

Vol 74, No 5 (2023)
Original Paper
Submitted: 2023-07-01
Accepted: 2023-08-16
Published online: 2023-10-23

Abstract

Introduction: Galectin-3 (Gal-3) and fetuin-A (Fet-A) are cytokines that participate in inflammation and insulin resistance. Previous studies have found that altered Gal-3 and Fet-A levels in circulation correlate with diabetic complications. However, whether they are all associated with diabetic retinopathy (DR) has been little investigated. The aim of this study was to assess plasma Gal-3 and Fet-A concentrations, and to investigate their associations with the presence of DR in type 2 diabetes mellitus (T2DM) patients.

Material and methods: A total of 100 T2DM patients were enrolled, among which there were 50 patients without DR (non diabetic retinopathy, NDR group) and 50 patients with DR (DR group). Clinical parameters were collected, and plasma Gal-3 and Fet-A levels were measured by enzyme-linked immunosorbent assay (ELISA).

Results: Both Gal-3 and Fet-A were found to be increased in DR patients with respect to NDR controls, and Gal-3 correlated positively with Fet-A. Bivariate correlation analysis revealed that Gal-3 levels were positively correlated with haemoglobin A1c (HbA1c), while Fet-A correlated negatively with fasting C peptide (FC-P) and positively with homocysteine (Hcy). Binary logistic regression suggested that elevated Gal-3 and Fet-A levels were related to increased risk of DR. ROC curve displayed that the combination of Fet-A and Gal-3 exhibited better diagnostic value for DR.

Conclusions: Both Gal-3 and Fet-A were elevated in the circulation of DR patients, and they were positively associated with the occurrence of DR. The combination of 2 indicators showed better diagnostic value for DR.

 

Abstract

Introduction: Galectin-3 (Gal-3) and fetuin-A (Fet-A) are cytokines that participate in inflammation and insulin resistance. Previous studies have found that altered Gal-3 and Fet-A levels in circulation correlate with diabetic complications. However, whether they are all associated with diabetic retinopathy (DR) has been little investigated. The aim of this study was to assess plasma Gal-3 and Fet-A concentrations, and to investigate their associations with the presence of DR in type 2 diabetes mellitus (T2DM) patients.

Material and methods: A total of 100 T2DM patients were enrolled, among which there were 50 patients without DR (non diabetic retinopathy, NDR group) and 50 patients with DR (DR group). Clinical parameters were collected, and plasma Gal-3 and Fet-A levels were measured by enzyme-linked immunosorbent assay (ELISA).

Results: Both Gal-3 and Fet-A were found to be increased in DR patients with respect to NDR controls, and Gal-3 correlated positively with Fet-A. Bivariate correlation analysis revealed that Gal-3 levels were positively correlated with haemoglobin A1c (HbA1c), while Fet-A correlated negatively with fasting C peptide (FC-P) and positively with homocysteine (Hcy). Binary logistic regression suggested that elevated Gal-3 and Fet-A levels were related to increased risk of DR. ROC curve displayed that the combination of Fet-A and Gal-3 exhibited better diagnostic value for DR.

Conclusions: Both Gal-3 and Fet-A were elevated in the circulation of DR patients, and they were positively associated with the occurrence of DR. The combination of 2 indicators showed better diagnostic value for DR.

 

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

type 2 diabetes mellitus; diabetic retinopathy; galectin-3; fetuin-A

About this article
Title

Association of plasma galectin-3 and fetuin-A levels with diabetic retinopathy in type 2 diabetes mellitus patients

Journal

Endokrynologia Polska

Issue

Vol 74, No 5 (2023)

Article type

Original paper

Pages

536-543

Published online

2023-10-23

Page views

364

Article views/downloads

337

DOI

10.5603/ep.96300

Bibliographic record

Endokrynol Pol 2023;74(5):536-543.

Keywords

type 2 diabetes mellitus
diabetic retinopathy
galectin-3
fetuin-A

Authors

Min Li
Meimei Tian
Yuling Wang
Huijie Ma
Yaru Zhou
Xinli Jiang
Yan Liu

References (39)
  1. Forrester JV, Kuffova L, Delibegovic M. The Role of Inflammation in Diabetic Retinopathy. Front Immunol. 2020; 11: 583687.
    CrossRefPubMed
  2. Antonetti DA, Silva PS, Stitt AW. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol. 2021; 17(4): 195–206.
    CrossRefPubMed
  3. Luís C, Soares R, Baylina P, et al. Underestimated Prediabetic Biomarkers: Are We Blind to Their Strategy? Front Endocrinol (Lausanne). 2022; 13: 805837.
    CrossRefPubMed
  4. Li M, Tian M, Jiang X, et al. Inhibition of galectin-3 ameliorates high-glucose-induced oxidative stress and inflammation in ARPE-19 cells. Cutan Ocul Toxicol. 2022; 41(2): 179–186.
    CrossRefPubMed
  5. Canning P, Glenn JV, Hsu DK, et al. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res. 2007; 2007: 51837.
    CrossRefPubMed
  6. Mendonça HR, Carvalho JN, Abreu CA, et al. Lack of Galectin-3 attenuates neuroinflammation and protects the retina and optic nerve of diabetic mice. Brain Res. 2018; 1700: 126–137.
    CrossRefPubMed
  7. Vora A, de Lemos JA, Ayers C, et al. Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study. J Clin Endocrinol Metab. 2019; 104(10): 4449–4458.
    CrossRefPubMed
  8. Lui DTW, Cheung CL, Lee ACH, et al. Galectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes. Diabetes Metab Res Rev. 2019; 35(2): e3093–809.
    CrossRefPubMed
  9. Hodeib H, Hagras MM, Abdelhai D, et al. Galectin-3 as a prognostic biomarker for diabetic nephropathy. Diabetes Metab Syndr Obes. 2019; 12: 325–331.
    CrossRefPubMed
  10. Atalar MN, Abuşoğlu S, Ünlü A, et al. Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes. Life Sci. 2019; 231: 116577.
    CrossRefPubMed
  11. Tan KCB, Cheung CL, Lee ACH, et al. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus. Diabetologia. 2018; 61(5): 1212–1219.
    CrossRefPubMed
  12. Yilmaz A, Yilmaz T, Gunay M. Elevated serum fetuin-A levels are associated with grades of retinopathy in type 2 diabetic patients. Int Ophthalmol. 2018; 38(6): 2445–2450.
    CrossRefPubMed
  13. Priya E, Jayashree K, Senthilkumar GP, et al. Role of Fetuin-A and vascular endothelial growth factor In type 2 diabetes mellitus patients without and with retinopathy. Diabetes Metab Syndr. 2019; 13(4): 2699–2703.
    CrossRefPubMed
  14. Zhou ZW, Ju HX, Sun MZ, et al. Serum fetuin-A levels are independently correlated with vascular endothelial growth factor and C-reactive protein concentrations in type 2 diabetic patients with diabetic retinopathy. Clin Chim Acta. 2016; 455: 113–117.
    CrossRefPubMed
  15. Zhou Z, Ju H, Sun M, et al. Serum fetuin-A concentrations are positively associated with serum VEGF levels in patients with newly diagnosed type 2 diabetes. Endocr J. 2015; 62(10): 879–885.
    CrossRefPubMed
  16. Wilkinson CP, Ferris FL, Klein RE, et al. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003; 110(9): 1677–1682.
    CrossRefPubMed
  17. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020; 37: 101799.
    CrossRefPubMed
  18. Song P, Yu J, Chan KY, et al. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health. 2018; 8(1): 010803.
    CrossRefPubMed
  19. Kumar S, Ranawat CS, Bhandiwad C, et al. Galectin-3 as a Potential Biomarker of Microvascular Complications in Patients with Type 2 Diabetes. Indian J Endocrinol Metab. 2022; 26(5): 490–497.
    CrossRefPubMed
  20. Li Y, Li T, Zhou Z, et al. Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot. Rev Endocr Metab Disord. 2022; 23(3): 569–577.
    CrossRefPubMed
  21. Winter MP, Wiesbauer F, Alimohammadi A, et al. Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest. 2016; 46(5): 386–391.
    CrossRefPubMed
  22. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012; 272(1): 55–64.
    CrossRefPubMed
  23. Gunes AE, Eren MA, Koyuncu I, et al. Investigation of galectin-3 levels in diabetic foot ulcers. J Wound Care. 2018; 27(12): 843–848.
    CrossRefPubMed
  24. Jin Qh, Lou Yf, Li Tl, et al. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med J (Engl). 2013; 126(11): 2109–2115.
    PubMed
  25. Weigert J, Neumeier M, Wanninger J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010; 95(3): 1404–1411.
    CrossRefPubMed
  26. Icer MA, Yıldıran H. Effects of fetuin-A with diverse functions and multiple mechanisms on human health. Clin Biochem. 2021; 88: 1–10.
    CrossRefPubMed
  27. Chattopadhyay M, Mukherjee S, Chatterjee SK, et al. Impairment of energy sensors, SIRT1 and AMPK, in lipid induced inflamed adipocyte is regulated by Fetuin A. Cell Signal. 2018; 42: 67–76.
    CrossRefPubMed
  28. Zhang LY, Qu XN, Sun ZY, et al. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2020; 44(5): 674–680.
    CrossRefPubMed
  29. El-Deeb TS, Bakkar SM, Eltoony L, et al. The adipokine Chemerin and Fetuin-A Serum Levels in Type 2 Diabetes Mellitus: Relation to Obesity and Inflammatory Markers. Egypt J Immunol. 2018; 25(1): 191–202.
    PubMed
  30. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008; 57(10): 2762–2767.
    CrossRefPubMed
  31. Ou HY, Yang YC, Wu HT, et al. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab. 2012; 97(12): 4717–4723.
    CrossRefPubMed
  32. Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, et al. The structure, biosynthesis, and biological roles of fetuin-A: A review. Front Cell Dev Biol. 2022; 10: 945287.
    CrossRefPubMed
  33. Wan H, Wang Y, Zhang K, et al. Associations Between Vitamin D and Microvascular Complications in Middle-Aged And Elderly Diabetic Patients. Endocr Pract. 2019; 25(8): 809–816.
    CrossRefPubMed
  34. Ashinne B, Rajalakshmi R, Anjana RM, et al. Association of serum vitamin D levels and diabetic retinopathy in Asian Indians with type 2 diabetes. Diabetes Res Clin Pract. 2018; 139: 308–313.
    CrossRefPubMed
  35. Luo BA, Gao F, Qin LL. The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies. Nutrients. 2017; 9(3).
    CrossRefPubMed
  36. Chi L, Li S, Shang X, et al. Correlation between serum 25-hydroxyvitamin D level and diabetic retinopathy: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(4): e23697.
    CrossRefPubMed
  37. Chan HN, Zhang XJ, Ling XT, et al. Vitamin D and Ocular Diseases: A Systematic Review. Int J Mol Sci. 2022; 23(8).
    CrossRefPubMed
  38. Alam U, Amjad Y, Chan AW, et al. Vitamin D Deficiency Is Not Associated with Diabetic Retinopathy or Maculopathy. J Diabetes Res. 2016; 2016: 6156217.
    CrossRefPubMed
  39. Xiao Y, Wei L, Xiong X, et al. Association Between Vitamin D Status and Diabetic Complications in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study in Hunan China. Front Endocrinol (Lausanne). 2020; 11: 564738.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl